Maravai LifeSciences (NASDAQ:MRVI) & DiaSorin (OTCMKTS:DSRLF) Critical Analysis

DiaSorin (OTCMKTS:DSRLF) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares DiaSorin and Maravai LifeSciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaSorin	$1.28 billion	N/A	$203.55 million	N/A	N/A
Maravai LifeSciences	$259.18 million	3.55	-$144.85 million	($0.84)	-4.29

DiaSorin has higher revenue and earnings than Maravai LifeSciences.

Insider and Institutional Ownership

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.1% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for DiaSorin and Maravai LifeSciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaSorin	0	0	2	0	3.00
Maravai LifeSciences	1	5	3	0	2.22

Maravai LifeSciences has a consensus price target of $5.36, indicating a potential upside of 48.81%. Given Maravai LifeSciences’ higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than DiaSorin.

Risk and Volatility

DiaSorin has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.

Profitability

This table compares DiaSorin and Maravai LifeSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DiaSorin	N/A	N/A	N/A
Maravai LifeSciences	-62.88%	-22.42%	-12.11%

Summary

DiaSorin beats Maravai LifeSciences on 6 of the 11 factors compared between the two stocks.

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.